339 related articles for article (PubMed ID: 21126267)
21. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
[TBL] [Abstract][Full Text] [Related]
22. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
24. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
25. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
[TBL] [Abstract][Full Text] [Related]
26. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
[TBL] [Abstract][Full Text] [Related]
27. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
28. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
[TBL] [Abstract][Full Text] [Related]
29. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
30. Antifungal treatment strategies in high risk patients.
Rüping MJ; Vehreschild JJ; Cornely OA
Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
[TBL] [Abstract][Full Text] [Related]
31. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia.
Devanlay C; Tavernier-Tardy E; Bourmaud A; Falk AT; Raberin H; Menguy S; Guyotat D; Magné N; Cornillon J
Biomed J; 2015; 38(3):235-43. PubMed ID: 25355388
[TBL] [Abstract][Full Text] [Related]
32. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
33. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
Pagano L; Verga L; Busca A; Martino B; Mitra ME; Fanci R; Ballanti S; Picardi M; Castagnola C; Cattaneo C; Nadali G; Nosari A; Candoni A; Caira M; Salutari P; Lessi F; Aversa F; Tumbarello M
J Antimicrob Chemother; 2014 Nov; 69(11):3142-7. PubMed ID: 24948702
[TBL] [Abstract][Full Text] [Related]
34. Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.
Brissot E; Cahu X; Guillaume T; Delaunay J; Ayari S; Peterlin P; Le Bourgeois A; Harousseau JL; Milpied N; Bene MC; Moreau P; Mohty M; Chevallier P
Ann Hematol; 2015 Apr; 94(4):663-9. PubMed ID: 25409914
[TBL] [Abstract][Full Text] [Related]
35. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
36. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
37. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
38. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
[TBL] [Abstract][Full Text] [Related]
40. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
